Abstract

Starting from the last of December to date, the pandemic onset of acute respiratory syndrome coronavirus 2 (SARS-CoV2) causing the COVID-19 (corona virus disease 2019) throughout the world appears extremely fatal on the aspect of public health with the highest rate of mortality amongst all disease outbreaks within the last hundred years. In the meantime, lots of novel works to unravel the protective mechanisms against this viral attack have been conducted; and even the specific antiviral vaccine has undergone the trial. The molecular mechanisms underlying the viral epidemiology have been well documented. Aside to lots of reports consisting of the in depth knowledge about the genetics, pathogenesis, the antibody-enhanced viral entry; the host immunity escaping strategies of the respiratory viruses as well the SARS-CoV2, the present review summed up the major molecular and immunological issues, especially the escaping means of the host innate immunity related to COVID-19 briefly and simply as an incremental knowledge for the public awareness.

Keywords: COVID-19; Epidemiology; Innate Immunity; Public Health

References

1. Chan JF., et al. “Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan”. Emerging Microbes and Infections 1 (2020): 221-236.
2. Ralph R., et al. “2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness”. Journal of Infection in Developing Countries 14 (2020): 3-17.
3. Zhao S., et al. “Preliminary estimation of the basic reproduction number of novelcoronavirus (2019-nCoV) in China, from 2019 to 2020: A data-drivenanalysis in the early phase of the outbreak”. International Journal of Infectious Diseases S1201-9712.20 (2010): 30053-30059.
4. WHO (World Health Organization). Origin of SARS-CoV-2 (2020).
5. Cascella M., et al. “Features, Evaluation and Treatment Coronavirus (COVID-19)”. StatPearls Publishing (2020).
6. World Health Organization (WHO). “Coronavirus disease 2019 (COVID-19) Situation Report – 95” (2020).
7. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 10224 (2020): 565-574.
8. Lai CC., et al. “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges 55.3 (2020): 105924.
9. Haider N., et al. “Passengers' destinations from China: low risk of Novel Coronavirus (2019-nCoV) transmission into Africa and South America”. Epidemiology and Infection 148 (2020): e41.
10. Wan Y., et al. “Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry”. Journal of Virology 5 (2020): e02015-e2019.
11. Kikkert M. “Innate Immune Evasion by Human Respiratory RNA Viruses”. The Journal of Innate Immunity 1 (2020): 4-20.
12. Wang Q., et al. “MERS-CoV spike protein: targets for vaccines and therapeutics”. Antiviral Research 133 (2016): 165-177.
13. Su S., et al. “Epidemiology, genetic recombination, and pathogenesis of coronaviruses”. Trends in Microbiology 24 (2016): 490-502.
14. Kanne JP. “Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist”. Radiology1 (2020): 16-17.
15. Martin TR and Frevert CW. “Innate immunity in the lungs”. Proceedings of the American Thoracic Society 5 (2005): 403-411.
16. Romero-Brey I and Bartenschlager R. “Membranous replication factories induced by plus-strand RNA viruses”. Viruses 7 (2017): 2826-2857.
17. Kindler E., et al. “Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication”. PLoS Pathogen2 (2017): e1006195.
18. De Vlugt C., et al. “Insight into Influenza: A Virus Cap-Snatching”. Viruses11 (2018): 641.
19. Rusek P., et al. “Infectious Agents as Stimuli of Trained Innate Immunity”. International Journal of Molecular Sciences 2 (2018): 456.
20. Netea MG., et al. “Trained immunity: A program of innate immune memory in health and disease”. Science 6284 (2016): aaf1098-aaf1098.
21. Han HJ., et al. “Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection”. Viruses 12 (2018): 680.
22. Morse JS., et al. “Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV”. Chemistry Chemical Biology 5 (2020): 730-738.
23. Lu H. “Drug treatment options for the 2019-new coronavirus (2019-nCoV)”. BioScience Trends 1 (2020): 69-71.
24. Rolain JM., et al. “Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21^st century”. The International Journal of Antimicrobial (2007): 297-308.
25. World Health Organization (WHO). Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations (2020).